Adial Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is…

Biotechnology
US, Charlottesville [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Adial Pharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ADIL's Analysis
CIK: 1513525 CUSIP: 00688A106 ISIN: US00688A2050 LEI: - UEI: -
Secondary Listings
ADIL has no secondary listings inside our databases.